Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippia finds jobs where you're a top candidate and applies on your behalf.
Optimer Pharmaceuticals received early financing of $32.0M on 2001-09-24.
| Series | Round size | Date |
|---|---|---|
| Series B | $32M | 09/2001 |
| Series C | $12M | 03/2005 |
| Series D | $22.2M | 12/2005 |
| Investors | Security type |
|---|---|
| China Development Industrial Bank (CDIB) | Series B |
| ProQuest Investments | Series B |
| ENDO INTERNATIONAL PLC | Series C |
| China Development Industrial Bank (CDIB) | Series D |
| SB Life Science | Series D |
| STRATEGIC GLOBAL INVESTMENTS | Series D |
| Fubon Bank | Series D |
| ProQuest Investments | Series D |
| Lurie Investment Fund | Series D |
| BB Biotech Ventures | Series D |
| YFY Biotech Management Company | Series D |
Optimer Pharmaceuticals's top competitor, Regeneron, earned an annual revenue of $14.2B.
Optimer Pharmaceuticals's smallest competitor is Onconova Therapeutics with revenue of $226.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Santarus | $70,584 | $218.0M | 290 | - |
| Anacor Pharmaceutical | $70,481 | $82.4M | 100 | - |
| PTC Therapeutics | $92,986 | $806.8M | 517 | 21 |
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 136 |
| OncoMed Pharmaceuticals | $80,625 | $44.4M | 83 | - |
| Regeneron | $85,589 | $14.2B | 9,123 | 340 |
| Cerexa Inc. | $46,963 | $1.3M | 29 | - |
| Acadia Pharmaceuticals | $90,533 | $957.8M | 570 | 101 |
| Achaogen | $46,646 | $8.7M | 42 | - |
| Onconova Therapeutics | $51,735 | $226,000 | 12 | - |
Zippia gives an in-depth look into the details of Optimer Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Optimer Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Optimer Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Optimer Pharmaceuticals. The data presented on this page does not represent the view of Optimer Pharmaceuticals and its employees or that of Zippia.
Optimer Pharmaceuticals may also be known as or be related to OPTIMER PHARMACEUTICALS INC and Optimer Pharmaceuticals.